Searched for
BIOCON BIOLOGICS IPO
The alchemist of Bengaluru: Kiran Mazumdar-Shaw began from a garageKiran Mazumdar-Shaw has named her niece Claire Mazumdar as successor, setting up a gradual leadership transition at Biocon. A pioneer who b...- ET Exclusive | Biologics merger with Biocon most value-accretive option: Kiran Mazumdar ShawBiocon is fully integrating Biocon Biologics, valuing its biosimilar business at $5.5 billion. This move removes debt concerns and improves...
- Biocon to make Biocon Biologics a wholly owned subsidiaryBiocon is set to fully integrate its biosimilar arm, Biocon Biologics. This move will make Biocon Biologics a wholly owned subsidiary. Bioc...
- Biocon shares jump 3% to hit new 52-week high on $4.5 billion Biologics IPO, merger reviewBiocon shares hit a new 52-week high after the company confirmed it is evaluating a potential merger of Biocon Biologics with the parent en...
- Biocon considers merging Biocon Biologics in $4.5 billion deal; IPO and share swap options under reviewBiocon is exploring merging its biosimilars arm, Biocon Biologics, with itself, potentially valuing the unit at $4.5 billion. The company i...
- Biocon reports 95% YoY decline in net profit, operating revenue up 15%Biocon's Q1 net profit declined 95% year-on-year, but on a like-for-like basis, profit after tax increased by 65%. Revenue grew 15% to Rs 3...
- Biocon plans ₹4,500-cr QIP to raise stake in Biologics unit: Kiran ShawBiocon is planning a ₹4,500 crore fundraise to increase promoter stake in Biocon Biologics and convert structured venture debt into equity,...
- Biocon plans IPO for biosimilars business by March 2026Biocon plans to list its biosimilars business by March 2026 and aims for a double-digit market share in the U.S. for five new biosimilars l...
- Biocon appoints Peter Bains as Group CEO"I am delighted to welcome Peter to the Biocon Group in the role of Group CEO. Siddharth Mittal, CEO & MD Biocon Limited, Shreehas Tambe, C...
- Biocon Biologics may raise additional equity of $300 million in FY24 to pare debtBiocon Biologics plans to raise a further $300m by the end of FY24 in order to reduce its net debt, which peaked at $1.9bn in December 2022...
- Viatris deal pinches Biocon, but may prove a good betThe $3.3-billion acquisition - that includes $2.3 billion cash and a 12.9% equity stake in BBL - stands at over half of the market cap of B...
- Biocon to use debt, equity and IPO to buy Viatris biosimilars biz: Kiran Mazumdar Shaw“It will be a mix of debt, equity and of course IPO. It is going to be a very interesting business opportunity and a very comfortable aspec...
- Biocon Biologics to file for IPO within next 2 years: Kiran Mazumdar-Shaw"And obviously, we expect the IPO to be at a very, very attractive level. So if you look at it, it's going to hugely create value for share...
- Biocon Biologics provided 7,000 doses of Itolizumab in AprilThe company does not look at Covid-19 related drugs as a business opportunity; it expects higher growth this fiscal year on the back of new...
- Covid has been a bit of a deterrent for creating new markets: Kiran Mazumdar ShawLatest funding in Biocon Biologics is a precursor to the IPO. The initial funding of $300 million plus very important to ensure that we rem...
- Biocon Biologics to expand to Latin America, Africa and Asia“We are investing thoughtfully to expand the global footprint step by step across the world. We have opened regional offices across Latin A...
- Biocon Biologics eyes $200m, plans IPO in 2 years: Mazumdar-ShawIt looks to build a pipeline of 28 biosimilars across global markets in three phases.
- True North to acquire 2.4% stake in Biocon BiologicsDeal values Biocon Biologics at $3 billion
- True North buys into Biocon Biologics, deal values firm at around $3.5 billionTrue North has acquired about 3 per cent of Biocon Biologics India Ltd (BBIL), a wholly owned subsidiary of Biocon, for $100 million, valui...
- First pharma IPO in 5 years: Syngene’s debut offer subscribed 32 timesThe Rs 550-crore initial public offer of Syngene, a research arm of Biocon, was subscribed 32 times on the final day of the offer
Load More
